Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIPHETAMINE 20 vs BIPHETAMINE 7.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.
Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.
Narcolepsy,Attention Deficit Hyperactivity Disorder (ADHD) (FDA-approved for these indications as a schedule II controlled substance)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.
Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.
0.5–1.5 hours for the immediate-release component; terminal elimination half-life of the total amphetamine salts is approximately 10–13 hours in adults
6-8 hours (amphetamine moiety), 10-13 hours (dextroamphetamine); clinical effects may outlast serum levels due to accumulation.
Metabolized primarily by the liver via CYP2D6 and to a lesser extent by CYP3A4. Major metabolic pathways include hydroxylation, deamination, and oxidation to benzoic acid derivatives. Excretion is primarily renal.
Hepatic metabolism via CYP2D6, deamination, and glucuronidation; major metabolites include 4-hydroxyamphetamine and hippuric acid.
Renal (90% as unchanged drug and metabolites, with approximately 30% unchanged); fecal (10%)
Renal: ~70-90% unchanged and as active metabolites; minor fecal elimination. Acidic urine (p H <5.6) increases excretion; alkaline urine (p H >7.0) decreases it.
16–20% (primarily to albumin)
~16-20%; primarily albumin and alpha-1-acid glycoprotein.
3–4 L/kg; indicates extensive tissue distribution
4-5 L/kg; extensive tissue distribution with high CNS penetration.
Oral: 75–100% (first-pass metabolism minimal)
PO: 75-100% (immediate-release); food delays absorption but does not affect total AUC.
e GFR <30 m L/min: contraindicated; e GFR 30-59 m L/min: use with caution, reduce dose by 50%.
GFR 15-29 m L/min: 50% of normal dose; GFR <15 m L/min: avoid use.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Children ≥6 years: initial 5 mg orally once daily; titrate by 5 mg weekly to max 20 mg/day.
Children 6-17 years: initial 2.5 mg orally once daily; may increase by 2.5-5 mg weekly; maximum 30 mg daily.
Initiate at 5 mg orally once daily; increase slowly with monitoring for cardiovascular effects.
Start at 2.5 mg orally once daily; increase by 2.5 mg weekly as tolerated; monitor for cardiovascular effects and insomnia.
WARNING: ABUSE AND DEPENDENCE. Biphetamine contains amphetamine and dextroamphetamine, which have a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
WARNING: ABUSE AND DEPENDENCE. Amphetamines have a high potential for abuse; prolonged use may lead to drug dependence; misuse may cause sudden death or serious cardiovascular events.
Cardiovascular: risk of sudden death or serious cardiovascular events, especially in patients with pre-existing cardiac abnormalities.,CNS effects: may cause psychotic or manic symptoms, aggression, seizures, and visual disturbances.,Growth suppression: may cause weight loss and growth retardation in children.,Peripheral vasculopathy: including Raynaud's phenomenon.,Serotonin syndrome: when co-administered with serotonergic drugs.,Potential for immediate hypersensitivity reactions.
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase may occur; monitor for hypertension and tachycardia.,Psychiatric adverse reactions: exacerbation of pre-existing psychosis, mania, aggression, or new psychotic/manic symptoms.,Long-term suppression of growth in children; monitor height and weight.,Seizures: may lower seizure threshold; discontinue if seizures occur.,Peripheral vasculopathy: Raynaud's phenomenon; monitor for digital changes.
Hypersensitivity to amphetamine or dextroamphetamine,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis risk),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (e.g., advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension),Motor tics or Tourette's syndrome (worsening possible)
Hypersensitivity to amphetamine or other sympathomimetic amines,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Glaucoma,Hyperthyroidism,Moderate to severe hypertension,Advanced arteriosclerosis,Symptomatic cardiovascular disease,History of drug abuse
Avoid foods and beverages high in caffeine or other stimulants (e.g., coffee, tea, cola, chocolate) as they may increase stimulant effects and risk of adverse reactions. Acidic foods (e.g., citrus fruits, juices) and vitamin C can decrease absorption; separate intake by at least 1 hour. Maintain a consistent meal schedule to minimize appetite suppression.
Avoid high-fat meals as they may delay absorption. Avoid excessive caffeine intake as it may potentiate stimulant effects and increase anxiety. Ensure adequate hydration to reduce the risk of dry mouth and constipation. No specific foods are contraindicated, but a balanced diet is recommended to mitigate appetite suppression.
First trimester: Limited data; possible increased risk of oral clefts and cardiovascular defects based on some studies. Second and third trimesters: Risk of prematurity, low birth weight, neonatal withdrawal syndrome, and potential for behavioral effects. Avoid use unless benefit outweighs risk.
Pregnancy category C. First trimester: possible increased risk of congenital malformations (e.g., cardiac, orofacial clefts) based on limited human data and animal studies. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (including irritability, hyperexcitability). Use only if potential benefit justifies risk.
Contraindicated in breastfeeding. Amphetamines are excreted in human milk (M/P ratio not established) and may cause infant agitation, poor feeding, and growth suppression. Discontinue drug or nursing.
Not recommended. Amphetamine is excreted into breast milk; M/P ratio not established. Potential for infant exposure causing adverse effects such as irritability, poor feeding, and sleep disturbance. American Academy of Pediatrics recommends contraindication.
No established dosage adjustments in pregnancy; use lowest effective dose for shortest duration. Increased clearance during pregnancy may require dose increase, but safety data insufficient. Avoid in pregnancy unless essential.
No established dosing guidelines. Pregnancy may alter pharmacokinetics of amphetamines due to increased plasma volume and hepatic metabolism; consider using the lowest effective dose. Monitor clinical response and adjust as needed.
Monitor for hypertension and tachycardia; avoid use in patients with cardiovascular disease, hyperthyroidism, or glaucoma. Use with caution in patients with a history of substance abuse. May exacerbate tics and Tourette syndrome. Do not administer late in the day due to insomnia risk. Discontinue if seizures occur.
Biphetamine 7.5 is a fixed-dose combination of amphetamine and dextroamphetamine (ratio 1:1) used for ADHD. Monitor for cardiovascular adverse effects including hypertension, tachycardia, and sudden cardiac death, especially in patients with structural cardiac abnormalities. Avoid in patients with a history of drug abuse due to high abuse potential. Use with caution in patients with bipolar disorder as it may induce manic episodes. Assess for growth suppression in pediatric patients during long-term therapy.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose upon awakening; avoid taking late in the day to prevent sleep problems.,Do not chew or crush tablets; swallow whole with water.,Avoid alcohol and caffeine while taking this medication.,Report any chest pain, palpitations, shortness of breath, or fainting immediately.,May cause dizziness or blurred vision; avoid driving until you know how it affects you.,Store at room temperature away from light and moisture.
Take the medication exactly as prescribed; do not increase the dose or frequency without consulting your doctor.,Avoid taking this medication late in the day to prevent sleep disturbances.,Report any chest pain, shortness of breath, or fainting immediately.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store in a secure location away from children and others to prevent misuse.,Attend regular follow-ups for blood pressure, heart rate, and growth monitoring (in children).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIPHETAMINE 20 vs BIPHETAMINE 7.5, answered by our medical review team.
BIPHETAMINE 20 is a Central Nervous System Stimulant that works by Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.. BIPHETAMINE 7.5 is a Central Nervous System Stimulant that works by Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIPHETAMINE 20 and BIPHETAMINE 7.5 depend on the specific clinical indication. These are both Central Nervous System Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIPHETAMINE 20 is: 10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.. The standard adult dose of BIPHETAMINE 7.5 is: Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIPHETAMINE 20 and BIPHETAMINE 7.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIPHETAMINE 20 is classified as Category C. First trimester: Limited data; possible increased risk of oral clefts and cardiovascular defects based on some studies. Second and third trimesters: Risk of prematurity, low birth . BIPHETAMINE 7.5 is classified as Category C. Pregnancy category C. First trimester: possible increased risk of congenital malformations (e.g., cardiac, orofacial clefts) based on limited human data and animal studies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.